{
  "scenario_id": "biotech_gene_editing_ethics_2025",
  "context": "Mid-sized biotechnology company developing CRISPR-based gene editing therapies for rare genetic diseases, facing critical decision on clinical advancement",
  "stakeholders": {
    "requester": "Chief Scientific Officer",
    "approvers": [
      "CEO",
      "Board of Directors",
      "Bioethics Committee Chair"
    ],
    "influencers": [
      "Regulatory Affairs Director",
      "Clinical Development Lead",
      "Patient Advocacy Groups",
      "Investors"
    ],
    "affected_parties": [
      "Future patients",
      "Healthcare providers",
      "Regulatory bodies",
      "Competitors"
    ]
  },
  "request": {
    "amount": "$85 million",
    "purpose": "Advance lead gene editing candidate into Phase 1 clinical trials",
    "urgency": "high",
    "justification": "Preclinical data shows 80% efficacy in disease models with acceptable safety profile; first-mover advantage in rare disease space"
  },
  "decision_process": [
    {
      "stage": "initial_ethics_review",
      "duration": "6 weeks",
      "activities": [
        "Bioethics committee consultation",
        "Patient advocacy group engagement",
        "Public opinion research"
      ],
      "outcome": "Conditional approval with enhanced monitoring requirements"
    },
    {
      "stage": "regulatory_strategy_session",
      "duration": "4 weeks",
      "activities": [
        "FDA consultation meetings",
        "Regulatory pathway analysis",
        "Competitive landscape assessment"
      ],
      "outcome": "Orphan drug designation recommended with accelerated approval pathway"
    },
    {
      "stage": "financial_due_diligence",
      "duration": "3 weeks",
      "activities": [
        "Cost-benefit analysis",
        "Market sizing study",
        "Investor sentiment assessment"
      ],
      "outcome": "Positive ROI projection with 65% probability of success"
    },
    {
      "stage": "board_approval_meeting",
      "duration": "1 week",
      "activities": [
        "Executive presentation",
        "Board Q&A session",
        "Final vote"
      ],
      "outcome": "Approved with conditions"
    }
  ],
  "business_impact": {
    "expected_revenue": "$500 million (5-year projection)",
    "projected_market_share": "35% in rare disease segment",
    "risk_factors": [
      "Regulatory rejection risk",
      "Ethical controversy",
      "Technical failure in trials",
      "Competitor advancement"
    ],
    "strategic_alignment": "Advances core mission of developing transformative genetic therapies"
  },
  "decision_outcome": "Approved",
  "implementation_timeline": "Phase 1 trials to begin Q2 2026",
  "monitoring_metrics": [
    "Clinical trial enrollment rates",
    "Regulatory milestone achievements",
    "Ethical compliance scores",
    "Investor confidence indicators"
  ]
}
